Term ends Jun 7, 2031 · High confidence
20-year base term ends Jul 6, 2031
Held by GlaxoSmithKline Biologicals S.A.
Filed Oct 5, 2017 as application 15/725,858 · Granted Jan 14, 2020
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
2011
2031
Clock starts
Jul 6, 2011
Jul 6, 2011
Term ends
Jun 7, 2031
Jun 7, 2031
Granted
Jan 14, 2020
Jan 14, 2020
base term
after the term ends
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,770,463, US 9,801,897.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
20
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 6, 2011, when application PCT/US2011/043104, the earliest non-provisional in its chain, was filed (this one was filed Oct 5, 2017) | Jul 6, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,770,463, US 9,801,897) | capped to Jun 7, 2031 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 7, 2031 | High confidence |
This family
| Application PCT/US2011/043104 | PCT application no patent term | no patent term |
| US 9,801,897 | In force Jul 2031 | Jul 2031 |
| US 10,532,067 | this patent Jun 2031 | Jun 2031 |
| US 11,291,682 | In force Jun 2031 | Jun 2031 |
| US 11,324,770 | In force Jun 2031 | Jun 2031 |
| US 11,596,645 | In force Jun 2031 | Jun 2031 |
| US 11,730,754 | In force no later than Jul 2031 | no later than Jul 2031 |
| US 11,690,865 | In force no later than Jul 2031 | no later than Jul 2031 |
8 of 20 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 30, 2019 Reel 49315, frame 146 | Geall, Andrew; Ramsauer, Katrin; Otten, Gillis; Mandl, Christian | Novartis Vaccines and Diagnostics, Inc. | Assignment of Assignor's Interest |
| May 30, 2019 Reel 49318, frame 607 | Novartis Vaccine and Diagnostics, Inc. | Novartis AG | Assignment of Assignor's Interest |
| May 30, 2019 Reel 49318, frame 789 | Novartis AG | GlaxoSmithKline Biologicals S.A. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2031
Term ends Jun 7, 2031. Maintenance fees still fall due before then
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,770,463, US 9,801,897.
Citations
58
later US patents cite this one
That is top 5% of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.